Abstract
The clinical conditions of 110 patients affected by myasthenia gravis (MG) were followed from two to twelve years. Patients with thymectomy showed a statistically higher percentage of clinical remissions than patients without thymectomy. In patients without clinical remission immunosuppressive drugs were prescribed in different schedule; the greater percentage of pharmacological remissions with less adverse effects was obtained with administration of prednisone 50–75 mg/die initially, than gradually reduced to smaller dosage in alternate day, associated to azathioprine. Plasmapheresis, performed in six cases not responders to immunosuppressive drugs, always showed a positive and even prolonged effect.
Sommario
Centodieci pazienti affetti da miastenia grave sono stati sottoposti a controlli clinici ripetuti lungo un periodo variabile da 2 a 12 anni. I pazienti operati di timectomia hanno presentato una percentuale di remissioni cliniche significativamente più elevata rispetto i pazienti non timectomizzati. La grande maggioranza dei pazienti che non hanno manifestato una remissione completa della sintomatologia clinica sono stati sottoposti a diversi programmi di terapia immunosuppressiva. La maggior percentuale di remissioni farmacologiche con minori effetti collaterali fu ottenuta con la somministrazione di una dose iniziale di prednisone di 50–75 mg/die, gradualmente ridotta nelle settimane successive ed infine somministrata a dì alterni, a cui veniva associata, dopo qualche settimana, azatioprina 1–2 mg/Kg/die. La plasmaferesi, eseguita su alcuni pazienti gravemente affetti dalla malattia, e che non rispondevano adeguatamente alle terapie farmacologiche, ha sempre manifestato un effetto positivo, e se ripetuta più volte nello stesso soggetto, anche durevole.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Compston D.A.S., Vincent A., Newsom-Davis J., Batchelor J.R.:Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103: 579–601, 1980.
Dau P.C., Lindstrom J.M., Cassel C.K., Denys E.H., Shev E.E., Spitler L.E.:Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. New Engl. J. Med. 297: 1134–1140, 1977.
Dau P.C.:Plasmapheresis therapy in myasthenia gravis. Muscle & Nerve, 3: 468–482, 1980.
Engel A.G., Lambert E.H., Santa T.:Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor endplate fine structure. Neurology (Minneap.), 23: 1273–1281, 1973.
Engel A.G.:Morphologic and immunopathologic findings in myasthenia gravis and in congenital myasthenic syndromes. J. Neurol. Neurosurg. Psychiatry, 43: 577–589, 1980.
Fambrough D.M., Drachman D.B., Satyamurti S.:Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 182: 293–295, 1973.
Genkins G., Papatestas A.E., Horowitz S.N., Kornfeld P.:Studies in myasthenia gravis: early thymectomy. Am. J. Med. 58: 517–524, 1975.
Grob D., Brunner N.G., Namba T.:The natural course of myasthenia gravis and effect of therapeutic measures. Ann. N. Y. Acad. Sci. 377: 652–669, 1981.
Keynes G.L.:The results of thymectomy in myasthenia gravis. B. Med. J. 2: 611–616, 1949.
Lindstrom J., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D.:Antibody to acetylcholine receptor in myasthenia gravis: prevalence clinical correlates and diagnostic value. Neurology (Minneap.)i 26: 1054–1059, 1976.
Lindstrom J.:Antibody specifities in autoimmune myasthenia gravis. In: Serratrice G. (ed.), Neuromuscolar disease. New York, Raven 481–484, 1984.
Lisak R.P., Levinson A.I., Zweiman B.:Autoimmune aspects of myasthenia gravis. Coneepts Immunopathol., vol. 2: 65–101, Karger, Basel, 1985.
Matell G.:Myasthenia gravis-An autoimmune receptor disease. Acta Neurol. Scand. suppl. 90, 65: 112–121, 1982.
Mertens H.G., Hertel G., Reuther P., Ricker K.:Effect of immunosuppressive drugs (azathioprine). Ann. N.Y. Acad. Sci. 377: 691–699, 1981.
Milner-Brown H.S., Miller R.G.:Time course of improved neuromuscolar function following plasmaexchange alone and plasmaexchange with prednisone/azathioprine in myasthenia gravis. J. Neurol. Sci. 57: 357–368, 1982.
Munsat T.L.:Anticholinesterase abuse in myasthenia gravis. J. Neurol. Sci. 64: 5–10, 1984.
Olanow C.W., Wechsler A.S., Roses A.D.:A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis. Ann. Surg. 196: 113–121, 1982.
Olanow C.W., Lane R.J.N., Roses A.D.:Thymectomy in late onset myasthenia gravis. Arch. Neurol. 39: 82–83, 1982.
Oosterhuis H.J.G.H.:Thymectomy in myasthenia gravis. A review. Ital. J. Neurol. Sci. 4: 399–407, 1983.
Pascuzzi R.M., Coslett H.B., Johns T.R.:Longterm corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann. Neurol. 15: 291–298, 1984.
Patten B.N.:Myasthenia gravis: review of diagnosis and management. Muscle & Nerve 1: 190–205, 1978.
Perlo V.P., Arnason B., Castleman B.:The thymus gland in elderly patients with myasthenia gravis. Neurology 25: 294–295, 1975.
Rodnitzky R.L., Bosh, E.P.:Chronic long-term plasmaexchange in myasthenia gravis. Arch. Neurol. 715–717, 1984.
Rowland L.P.:Controversies about the treatment of myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 43: 644–649, 1980.
Scadding G.K., Havard C.W.H., Lange M.J., Domb I.:The long term experience of thymectomy for myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 48: 401–406, 1985.
Scoppetta C., Tonali P., Evoli A., David P., Crucitti F., Vaccario M.L.:Treatment of myasthenia gravis. Report on 139 patients. J. Neurol. 222: 11–21, 1979.
Seybold M.E., Lindstrom J.M.:Patterns of acetylcholine receptor antibody fluctuation in myasthenia gravis. Ann. N. Y. Acad. Sci. 377: 292–306, 1981.
Sghirlanzoni A., Pelucchetti D., Mantegazza R., Fiacchino F., Cornelio F.:Myasthenia gravis prolonged treatment with steroids. Neurology (Cleveland) 34: 170–174, 1984.
Humm F., Wietholter H., Fateh-Moghadam A., Dichgans J.:Thymectomy in myasthenia with pure ocular symptoms. J. Neurol. Neurosurg. Psychiatry 48: 332–337, 1985.
Simpson J.A.:The thymus in the pathogenesis and treatment of myasthenia gravis. In: Satoyoshi E. (ed) Myasthenia Gravis, Tokyo, 301–307 (1981).
Tarrab-Hazdai R., Aharanov A., Abramsky O., Yaar I., Fuchs S.:Passive transfer of experimental autoimmune myasthenia by lymphonode cells in inbred guinea pigs. J. Exp. Med. 142: 785–789, 1975.
Tindall R.S.A.:Humoral immunity in myasthenia gravis: effects of steroids and thymectomy. Neurology (NY) 30: 554–557, 1980.
Vincent A., Newsom-Davis J.:Anti-acetylcholine receptor antibodies. J. Neurol. Neurosurg. Psychiatry 43: 590–600, 1980.
Author information
Authors and Affiliations
Additional information
This study has been partially supported by “Legato Dino Ferrari”.
Rights and permissions
About this article
Cite this article
Valli, G., Jann, S., Premoselli, S. et al. Myasthenia gravis treatment: twelve years experience on 110 patients. Ital J Neuro Sci 8, 593–601 (1987). https://doi.org/10.1007/BF02333667
Issue Date:
DOI: https://doi.org/10.1007/BF02333667